Adamas Pharmaceuticals Inc Revenue Growth Rates (ADMS), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Adamas Pharmaceuticals Inc  (NASDAQ: ADMS)
 

ADMS's Revenue Growth by Quarter and Year

Adamas Pharmaceuticals Inc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ADMS Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter December -
3rd Quarter September 25.90
2nd Quarter June 21.97
1st Quarter March 19.31
FY 67.18

ADMSs Annual Revenue
Adamas Pharmaceuticals Inc's Revenue in the fiscal year 2020 $ 74.46 millions
Adamas Pharmaceuticals Inc's Revenue in the fiscal year 2019 $ 54.64 millions
Adamas Pharmaceuticals Inc's Revenue in the fiscal year 2018 $ 34.05 millions
Adamas Pharmaceuticals Inc's Revenue in the fiscal year 2017 $ 0.57 millions
Adamas Pharmaceuticals Inc's Revenue in the fiscal year 2016 $ 0.57 millions




ADMS Revenue third quarter 2021 Y/Y Growth Comment
Adamas Pharmaceuticals Inc reported Revenue improvement of 28.33% year on year in the third quarter 2021, to $ 25.90 millions, this is lower than Adamas Pharmaceuticals Inc's recent average Revenue surge of 55510.81%.

Looking into third quarter 2021 results within Major Pharmaceutical Preparations industry 91 other companies have achieved higher Revenue growth. While Adamas Pharmaceuticals Inc' s Revenue rise of 28.33% ranks overall at the positon no. 1232 in the third quarter 2021.


ADMS Revenue ( Y/Y Growth %) 2021
 2020 2019 2018
4th Quarter December - 28.5 % 22.75 % 2236.84 %
3rd Quarter September 28.33 % 44.87 % 31.29 % -
2nd Quarter June 16.92 % 48.07 % 67.64 % -
1st Quarter March 33.36 % 24.08 % 357.65 % -
FY   - 36.27 % 60.47 % -

Financial Statements
Adamas Pharmaceuticals Inc's third quarter 2021 Revenue $ 25.90 millions ADMS's Income Statement
Adamas Pharmaceuticals Inc's third quarter 2020 Revenue $ 20.18 millions Quarterly ADMS's Income Statement


ADMS Revenue (Quarter on Quarter Growth %)

 2021
 2020 2019 2018
4th Quarter December - 4.11 % 17.37 % 25.54 %
3rd Quarter September 17.87 % 7.4 % 9.77 % 40.16 %
2nd Quarter June 13.78 % 29.77 % 8.74 % 196.86 %
1st Quarter March -8.09 % -11.44 % -12.39 % 347.37 %
FY (Year on Year)   - 36.27 % 60.47 % -


Back to ADMS Growth rate Comparisons >> Back to ADMS Growth rate Comparisons >>


Revenue third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #92
Healthcare Sector #199
Overall #1232

Revenue Y/Y Growth Statistics
High Average Low
1061200 % 55510.81 % -100 %
(Sep 30 2018)   (Mar 31 2017)
Revenue third quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #92
Healthcare Sector #199
Overall #1232
Revenue Y/Y Growth Statistics
High Average Low
1061200 % 55510.81 % -100 %
(Sep 30 2018)   (Mar 31 2017)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Adamas Pharmaceuticals Inc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
56700 % 2938.35 % -100 %
(Dec 31 2017)  


ADMS's III. Quarter Q/Q Revenue Comment
Adamas Pharmaceuticals Inc achieved in the III. Quarter 2021 below company average Revenue jump of 17.87% quarter on quarter, to $ 25.90 millions.

Although the III. Quarter 2021 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the III. Quarter surge, eclipses the 7.4% growth in the III. Quarter a year ago

Within Major Pharmaceutical Preparations industry 59 other companies have achieved higher Revenue quarter on quarter growth. While Adamas Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 618.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #125
Overall #618
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #60
Healthcare Sector #125
Overall #618
Revenue Q/Q Growth Statistics
High Average Low
56700 % 2938.35 % -100 %
(Dec 31 2017)  


ADMS's III. Quarter Q/Q Revenue Comment
Adamas Pharmaceuticals Inc achieved in the III. Quarter 2021 below company average Revenue jump of 17.87% quarter on quarter, to $ 25.90 millions.

III. Quarter 2021 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 7.4% in the III. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 59 other companies have achieved higher Revenue quarter on quarter growth. While Adamas Pharmaceuticals Inc's Revenue growth quarter on quarter, overall rank is 618.


Adamas Pharmaceuticals Inc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Sep 30 2021)		 12 Months Ending
(Jun 30 2021)		 12 Months Ending
(Mar 31 2021)		 12 Months Ending
(Dec 31 2020)		 12 Months Ending
(Sep 30 2020)
Cumulative Revenue 12 Months Ending $ 88.19 $ 82.47 $ 79.29 $ 74.46 $ 69.80
Y / Y Revenue Growth (TTM) 26.35 % 29.76 % 38.01 % 36.28 % 35.26 %
Year on Year Revenue Growth Overall Ranking # 837 # 857 # 329 # 237 # 224
Seqeuential Revenue Change (TTM) 6.94 % 4.01 % 6.49 % 6.68 % 9.82 %
Seq. Revenue Growth (TTM) Overall Ranking # 2130 # 1857 # 1078 # 529 # 2359


Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2021 period, Adamas Pharmaceuticals Inc's cumulative twelve months Revenue were $ 88 millions, company would post below average annual Revenue growth of 9.82% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Adamas Pharmaceuticals Inc's Revenue growth from the 21.97% growth in Jun 30 2021.

In the Healthcare sector 170 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 837, from total ranking in previous quarter at 857.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 107
Healthcare Sector # 171
Overall # 837

Revenue TTM Y/Y Growth Statistics
High Average Low
1281.5 %
 91.22 %
-96.66 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 107
Sector # 313
S&P 500 # 2130
Cumulative Revenue growth Comment
With the quarterly Revenue reported in the Sep 30 2021 period, Adamas Pharmaceuticals Inc's cumulative twelve months Revenue were $ 88 millions, company would post below average annual Revenue growth of -96.66% year on year, if the fiscal year would end at Sep 30 2021.
A slow-down in the Adamas Pharmaceuticals Inc's Revenue growth from the 21.97% growth in Jun 30 2021.

In the Healthcare sector 170 other companies have achieved higher trailing twelve month Revenue growth. While Total ranking has impoved so far to 837, from total ranking in previous quarter at 857.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 107
Healthcare Sector # 171
Overall # 837

Revenue TTM Y/Y Growth Statistics
High Average Low
1281.5 %
91.22 %
-96.66 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 107
Sector # 313
S&P 500 # 2130




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
ADMS's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Sep 30 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Sep 30 2021
Alnylam Pharmaceuticals Inc 49.09%$ 49.089 millions
1life Healthcare Inc 48.85%$ 48.852 millions
Syros Pharmaceuticals Inc 48.82%$ 48.824 millions
La Jolla Pharmaceutical Company46.76%$ 46.759 millions
Agilon Health Inc 46.67%$ 46.670 millions
Cutera Inc 46.64%$ 46.642 millions
Electromedical Technologies Inc 46.28%$ 46.285 millions
Aerie Pharmaceuticals Inc 45.97%$ 45.974 millions
Epizyme Inc.45.85%$ 45.850 millions
Biolase Inc 45.76%$ 45.756 millions
Tandem Diabetes Care Inc 45.33%$ 45.326 millions
Acutus Medical Inc 45.00%$ 45.005 millions
Mannkind Corporation44.68%$ 44.678 millions
Butterfly Network Inc 44.26%$ 44.262 millions
Tela Bio Inc 44.06%$ 44.062 millions
American Shared Hospital Services43.77%$ 43.774 millions
Htg Molecular Diagnostics Inc41.83%$ 41.827 millions
Iradimed Corporation41.67%$ 41.670 millions
Caredx Inc 41.63%$ 41.635 millions
T2 Biosystems Inc 41.62%$ 41.621 millions
Optinose Inc 41.40%$ 41.397 millions
Global Blood Therapeutics Inc.41.10%$ 41.104 millions
Somalogic Inc 40.46%$ 40.462 millions
Kymera Therapeutics Inc 39.93%$ 39.930 millions
Jazz Pharmaceuticals Plc39.48%$ 39.479 millions
Rxsight Inc 38.75%$ 38.753 millions
Avita Medical Inc 38.74%$ 38.735 millions
Nexgel Inc 38.43%$ 38.430 millions
Align Technology inc 38.38%$ 38.380 millions
Immucell Corporation38.35%$ 38.352 millions


About Adamas Pharmaceuticals Inc Revenue Growth Rates (ADMS), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.